These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

315 related items for PubMed ID: 24957832

  • 1. Characterization of drug-resistant influenza virus A(H1N1) and A(H3N2) variants selected in vitro with laninamivir.
    Samson M, Abed Y, Desrochers FM, Hamilton S, Luttick A, Tucker SP, Pryor MJ, Boivin G.
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5220-8. PubMed ID: 24957832
    [Abstract] [Full Text] [Related]

  • 2. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013-2014.
    Takashita E, Meijer A, Lackenby A, Gubareva L, Rebelo-de-Andrade H, Besselaar T, Fry A, Gregory V, Leang SK, Huang W, Lo J, Pereyaslov D, Siqueira MM, Wang D, Mak GC, Zhang W, Daniels RS, Hurt AC, Tashiro M.
    Antiviral Res; 2015 May; 117():27-38. PubMed ID: 25721488
    [Abstract] [Full Text] [Related]

  • 3. Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan.
    Dapat C, Kondo H, Dapat IC, Baranovich T, Suzuki Y, Shobugawa Y, Saito K, Saito R, Suzuki H.
    Antiviral Res; 2013 Sep; 99(3):261-9. PubMed ID: 23791870
    [Abstract] [Full Text] [Related]

  • 4. In Vitro and In Vivo Characterization of Novel Neuraminidase Substitutions in Influenza A(H1N1)pdm09 Virus Identified Using Laninamivir-Mediated In Vitro Selection.
    Lloren KKS, Kwon JJ, Choi WS, Jeong JH, Ahn SJ, Choi YK, Baek YH, Song MS.
    J Virol; 2019 Mar 15; 93(6):. PubMed ID: 30602610
    [Abstract] [Full Text] [Related]

  • 5. Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during the 2011 Southern Hemisphere season.
    Okomo-Adhiambo M, Sleeman K, Lysén C, Nguyen HT, Xu X, Li Y, Klimov AI, Gubareva LV.
    Influenza Other Respir Viruses; 2013 Sep 15; 7(5):645-58. PubMed ID: 23575174
    [Abstract] [Full Text] [Related]

  • 6. Structural and functional analysis of laninamivir and its octanoate prodrug reveals group specific mechanisms for influenza NA inhibition.
    Vavricka CJ, Li Q, Wu Y, Qi J, Wang M, Liu Y, Gao F, Liu J, Feng E, He J, Wang J, Liu H, Jiang H, Gao GF.
    PLoS Pathog; 2011 Oct 15; 7(10):e1002249. PubMed ID: 22028647
    [Abstract] [Full Text] [Related]

  • 7. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015-2016.
    Gubareva LV, Besselaar TG, Daniels RS, Fry A, Gregory V, Huang W, Hurt AC, Jorquera PA, Lackenby A, Leang SK, Lo J, Pereyaslov D, Rebelo-de-Andrade H, Siqueira MM, Takashita E, Odagiri T, Wang D, Zhang W, Meijer A.
    Antiviral Res; 2017 Oct 15; 146():12-20. PubMed ID: 28802866
    [Abstract] [Full Text] [Related]

  • 8. Duration of fever in children infected with influenza A(H1N1)pdm09, A(H3N2) or B virus and treated with baloxavir marboxil, oseltamivir, laninamivir, or zanamivir in Japan during the 2012-2013 and 2019-2020 influenza seasons.
    Sun Y, Wagatsuma K, Saito R, Sato I, Kawashima T, Saito T, Shimada Y, Ono Y, Kakuya F, Minato M, Kodo N, Suzuki E, Kitano A, Chon I, Phyu WW, Li J, Watanabe H.
    Antiviral Res; 2024 Aug 15; 228():105938. PubMed ID: 38897317
    [Abstract] [Full Text] [Related]

  • 9. Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro.
    Gubareva LV, Trujillo AA, Okomo-Adhiambo M, Mishin VP, Deyde VM, Sleeman K, Nguyen HT, Sheu TG, Garten RJ, Shaw MW, Fry AM, Klimov AI.
    Antivir Ther; 2010 Aug 15; 15(8):1151-9. PubMed ID: 21149922
    [Abstract] [Full Text] [Related]

  • 10. Cell culture-selected substitutions in influenza A(H3N2) neuraminidase affect drug susceptibility assessment.
    Tamura D, Nguyen HT, Sleeman K, Levine M, Mishin VP, Yang H, Guo Z, Okomo-Adhiambo M, Xu X, Stevens J, Gubareva LV.
    Antimicrob Agents Chemother; 2013 Dec 15; 57(12):6141-6. PubMed ID: 24080660
    [Abstract] [Full Text] [Related]

  • 11. Antiviral susceptibility of variant influenza A(H3N2)v viruses isolated in the United States from 2011 to 2013.
    Sleeman K, Mishin VP, Guo Z, Garten RJ, Balish A, Fry AM, Villanueva J, Stevens J, Gubareva LV.
    Antimicrob Agents Chemother; 2014 Dec 15; 58(4):2045-51. PubMed ID: 24449767
    [Abstract] [Full Text] [Related]

  • 12. In vitro neuraminidase inhibitory concentration (IC50) of four neuraminidase inhibitors in the Japanese 2018-19 season: Comparison with the 2010-11 to 2017-18 seasons.
    Ikematsu H, Kawai N, Tani N, Chong Y, Bando T, Iwaki N, Kashiwagi S.
    J Infect Chemother; 2020 Aug 15; 26(8):775-779. PubMed ID: 32249161
    [Abstract] [Full Text] [Related]

  • 13. In vitro neuraminidase inhibitory activities of four neuraminidase inhibitors against influenza viruses isolated in the 2010-2011 season in Japan.
    Ikematsu H, Kawai N, Kashiwagi S.
    J Infect Chemother; 2012 Aug 15; 18(4):529-33. PubMed ID: 22370919
    [Abstract] [Full Text] [Related]

  • 14. Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza.
    Ikematsu H, Kawai N.
    Expert Rev Anti Infect Ther; 2011 Oct 15; 9(10):851-7. PubMed ID: 21973296
    [Abstract] [Full Text] [Related]

  • 15. Neuraminidase inhibitor susceptibility of swine influenza A viruses isolated in Germany between 1981 and 2008.
    Bauer K, Dürrwald R, Schlegel M, Pfarr K, Topf D, Wiesener N, Dahse HM, Wutzler P, Schmidtke M.
    Med Microbiol Immunol; 2012 Feb 15; 201(1):61-72. PubMed ID: 21688167
    [Abstract] [Full Text] [Related]

  • 16. Clinical effectiveness of neuraminidase inhibitors--oseltamivir, zanamivir, laninamivir, and peramivir--for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010-2011 influenza season in Japan.
    Shobugawa Y, Saito R, Sato I, Kawashima T, Dapat C, Dapat IC, Kondo H, Suzuki Y, Saito K, Suzuki H.
    J Infect Chemother; 2012 Dec 15; 18(6):858-64. PubMed ID: 22644080
    [Abstract] [Full Text] [Related]

  • 17. In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against clinical isolates of influenza virus in the Japanese 2012-2013 season.
    Ikematsu H, Kawai N, Iwaki N, Kashiwagi S.
    J Infect Chemother; 2015 Jan 15; 21(1):39-42. PubMed ID: 25277670
    [Abstract] [Full Text] [Related]

  • 18. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012-2013.
    Meijer A, Rebelo-de-Andrade H, Correia V, Besselaar T, Drager-Dayal R, Fry A, Gregory V, Gubareva L, Kageyama T, Lackenby A, Lo J, Odagiri T, Pereyaslov D, Siqueira MM, Takashita E, Tashiro M, Wang D, Wong S, Zhang W, Daniels RS, Hurt AC.
    Antiviral Res; 2014 Oct 15; 110():31-41. PubMed ID: 25043638
    [Abstract] [Full Text] [Related]

  • 19. In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against clinical isolates of the influenza virus circulating in the Japanese 2013-2014 season.
    Ikematsu H, Kawai N, Iwaki N, Kashiwagi S.
    J Infect Chemother; 2015 Sep 15; 21(9):634-8. PubMed ID: 26096495
    [Abstract] [Full Text] [Related]

  • 20. Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance.
    McKimm-Breschkin JL.
    Influenza Other Respir Viruses; 2013 Jan 15; 7 Suppl 1(Suppl 1):25-36. PubMed ID: 23279894
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.